Related Experiment Video
Updated: Aug 26, 2025
05:49
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
Published on: November 1, 2024
895
[Novel Migraine Treatment: From Bench to Bedside]
1Department of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|October 5, 2022
Summary
New migraine treatments targeting calcitonin gene-related peptide (CGRP) show promise. Monoclonal antibodies and lasmiditan offer improved prevention and acute care by leveraging CGRP
Area of Science:
- Neurology
- Pharmacology
Background:
- Calcitonin gene-related peptide (CGRP) is integral to migraine pathophysiology.
- Existing migraine treatments have limitations in efficacy and side effect profiles.
Purpose of the Study:
- To review advancements in migraine treatment based on CGRP research.
- To highlight novel therapeutic strategies for acute and preventive migraine management.
Main Methods:
- Review of recent scientific literature on CGRP and migraine.
- Analysis of emerging therapeutic agents, including monoclonal antibodies and receptor agonists.
Main Results:
- Monoclonal antibodies targeting CGRP or its receptor demonstrate significant efficacy for migraine prevention.
- Lasmiditan, a serotonin 1F receptor agonist, offers a non-vasoconstricting option for acute migraine treatment by acting on central and peripheral nervous system sites.
- These advancements represent a paradigm shift in migraine therapy.
Conclusions:
- Targeting CGRP has revolutionized migraine treatment, offering improved options for patients.
- Translational research from basic science to clinical application has led to a new era in migraine management.
